​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​

Modernization
Workgroups
Memorandums
Payers
Legal and Legislative
Acct and Budget Manual
Data Request
Patient Complaint Information
Trustee Disclosure Information
ED Wait Time Reduction Commission

HSCRC Overview

Welcome to the HSCRC
The Maryland Health Services Cost Review Commission (HSCRC) is an independent state agency ensuring all Marylanders have access to high-value, affordable healthcare. We regulate hospital rates, advance health system transformation, and support the innovative Total Cost of Care Model and AHEAD Model to improve care quality, health outcomes, and cost-efficiency.​​​​
el and AHEAD Model to improve care quality, health outcomes, and cost-efficiency.​​​​

​​Notice is hereby given that the public and interested parties are invited to submit written comments to the Commission on the following topic: 

Discussion on Principles for Physician Payment, as presented at the December 10, 2025 Commission meeting. Based on Commissioner discussion, potential principles have been revised from the original presentation. Please see the revised potential principles for comment below.

WRITTEN COMMENTS ON THE DISCUSSION POINTS OUTLINED BELOW AND ON THE STAFF PRESENTATION SHALL BE SUBMITTED TO [email protected] ON OR BEFORE January 5, 2026.

Background
The HSCRC has identified rising costs of hospital-based physicians as a financial challenge facing hospitals. These costs include the need to supplement insurance reimbursements, provide payment for coverage, and respond to market dynamics that include the involvement of private equity-backed companies in employing physician groups.

A recent review of data suggests that physician costs can explain a large share of the difference between regulated margins and operating margins in the state. 

Under Maryland statute, the Commission cannot provide funds to support physician costs. There has been resulting interest in whether additional state programs or policies would further the goals of the model. The HSCRC is interested in public comment on principles for potential state initiatives regarding physician costs.

Of note, the new AHEAD agreement does not provide for additional Medicare funds to cover physician costs through hospital global budgets.

Potential Principles for Comment
HSCRC will develop principles to support decision-making on potential physician cost initiatives. Examples of such principles might include:

  1. ​Funding for physicians should focus on hospital-based physicians necessary for the administration of an efficient hospital. 
  2. Funding for physicians should facilitate the goals of the model, including improving quality, improving health outcomes, and reducing overall costs. 
  3. Funding for physicians should be paired with efforts to reduce underlying cost drivers.
  4. Funding for physicians should support care delivery innovations that solve broader challenges of the health care delivery system. 
  5. Funding for physicians should be available fairly to all hospital-based physicians. 
  6. Funding for physicians should be aligned with EQIP, MDPCP, and/or other value-based payment programs within the state.
  7. Funding for physicians should be coordinated with CMS so that Medicare and Medicaid participate. 


​​Notices​
  • RY 2028 MHAC Comment Letter Extension
    The comment letter due date for the RY 2028 Maryland Hospital Acquired Conditions (MHAC) Draft Policy issued to the public on December 3, 2025 has been changed.  The initial due date of December 18, 2025 has been changed to December 22, 2025.
    Please submit all comments to [email protected]

  • Volume Workgroup

HSCRC will hold the 5th Volume Workgroup virtually on December 18th at 1:00 PM. Meeting materials have been emailed to workgroup members. 

​Join Zoom Meeting 

Meeting ID: 410 764 2605
Passcode: 9Hm89B

  • Maryland Medicaid's participation in the Cell and Gene Therapy Access Model

In 2024, the Centers for Medicare and Medicaid Services (CMS) announced a new model, under the Center for Medicare and Medicaid Innovation (CMMI), to aid in the treatment of sickle cell disease (SCD). The model is the Cell and Gene Therapy Access Model (Model). The purpose of this Model is to expand access to gene therapy for SCD, provide access to critical supports and services, and cover ancillary services and, for interested participants, fertility preservation services. 

CMS, on States behalf, negotiated key terms of an outcomes-based agreement (OBA) with two manufacturers of gene therapies for SCD. The two manufacturers are Vertex Pharmaceuticals, Incorporated for CASGEVY™ and Genetix Biotherapeutics for LYFGENIA™. Facilities go through an application process with each manufacturer to become an authorized or qualified treatment center (A/QTC). 

Maryland Medicaid applied to participate in the Model and was accepted in the Spring of 2025. Maryland Medicaid's participation in the Model will begin on January 1, 2026. As part of this innovative model, reimbursement to the A/QTCs for the medications CASGEVY™ and  LYFGENIA™ will be at no less than the actual acquisition cost (AAC) of the gene therapies. For Maryland Medicaid, these two medications are not subject to the public payer differential.
​​

  • Annual Filing Modernization Project
    HSCRC is modernizing annual hospital filings through collaborative surveys and workgroups. Learn More.

  • Sexual Orientation and Gender Identity (SOGI) Data Collection
    Starting October 2025, hospitals will submit SOGI data to enhance inclusive, patient-centered care. Training resources are available. Learn More.

 Maryland's Total Cost of Care and AHEAD Model
​HSCRC plays a pivotal role in Maryland's groundbreaking Total Cost of Care Model, which transforms healthcare delivery to improve outcomes and control costs, and the AHEAD Model, which will start in 2026. Learn More.

Stay Connected
Have questions or suggestions? We’re here to help. Contact Us​